<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224818</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2018-0020</org_study_id>
    <nct_id>NCT04224818</nct_id>
  </id_info>
  <brief_title>Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders</brief_title>
  <official_title>Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG
      and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in
      patients with poor ovarian reserve seeking IVF/ICSI treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved (oocyte collection rate)</measure>
    <time_frame>38 hrs</time_frame>
    <description>the total number of oocytes retrieved divided by the number of follicles aspirated (diameter â‰¥10 mm) on the day of oocyte retrieval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of mature oocytes (oocyte maturation rate)</measure>
    <time_frame>38 hrs</time_frame>
    <description>the ratio of MII oocytes to the number of collected oocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>48 hrs</time_frame>
    <description>the ratio of normal fertilized oocytes (2PN) to the number of oocytes used for fertilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>the presence of fetal cardiac activity confirmed by transvaginal ultrasound 7 weeks after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>7 weeks</time_frame>
    <description>the number of gestational sacs visualized on ultrasound examination divided by the number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>the spontaneous loss of a clinical pregnancy occurring before 12 completed weeks of gestational age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Poor Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Dual trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG (standard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual trigger</intervention_name>
    <description>Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)</description>
    <arm_group_label>Dual trigger</arm_group_label>
    <arm_group_label>hCG (standard)</arm_group_label>
    <other_name>Dual ovulation trigger (Choriomon and Triptorelin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal uterine cavity (as assessed by hysteroscopy or HSG).

          -  Normal hormonal investigation: TSH, PRL.

          -  Low ovarian reserve patients (AMH&lt;1.5ng/ml, AFC of 7 or less, 5 oocytes or less
             retrieved in a previous cycle)

        Exclusion Criteria:

          -  Abnormal uterine cavity (Hysteroscopy or HSG)

          -  Evidence of untreated endocrine disorders (abnormal TSH, prolactin, testosterone and
             androstenedione concentrations)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ghina S Ghazeeri, MD</last_name>
    <phone>01350000</phone>
    <phone_ext>5618</phone_ext>
    <email>gg02@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghina S Ghazeeri, MD</last_name>
      <phone>01350000</phone>
      <phone_ext>5618</phone_ext>
      <email>gg02@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

